Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock.
In the psychedelic space, catalysts could be even more important, as the industry as a whole is still in its infancy.
At the Benzinga Psychedelic Capital Conference, four thought leaders sat down Tuesday for a panel discussion regarding upcoming catalysts for the psychedelic industry.
The four panelists were Doug Drysdale, CEO of Cybin Inc (NYSE: CYBN); Joel Stanley, CEO …